SCHEMBL568276

SCHEMBL568276

CC(C)(C)N(C(=O)O)C(=S)NCC1CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.40
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
CYP2D6 P10635 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
EPHX1 P07099 2/20 0.33
OPRK1 P41145 2/20 0.32
MAPT P10636 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
ALDH1A1 P00352 2/20 0.32
CYP3A4 P08684 1/20 0.32
ACACB O00763 1/20 0.32
ACACA Q13085 1/20 0.32
PKM P14618 2/20 0.32
KDM4E B2RXH2 1/20 0.32
OPRD1 P41143 1/20 0.32
CYP2C19 P33261 1/20 0.31
CA12 O43570 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL286191 0.70 LMNA (0.32) L3MBTL1
SCHEMBL12057456 0.68 TDP1 (0.54) TDP1KMT2ACYP2D6EPHX1OPRK1
SCHEMBL862986 0.67
SCHEMBL217411 0.65
SCHEMBL4396572 0.65 CYP2D6 (0.63) TDP1KMT2AMEN1CYP2D6EPHX1
SCHEMBL4396576 0.65 CYP2D6 (0.63) TDP1KMT2AMEN1CYP2D6EPHX1
SCHEMBL14000494 0.65 TDP1 (0.45) TDP1KMT2AMEN1CYP2D6SMN1; SMN2
SCHEMBL1584251 0.64 SAT1 (0.38) TDP1KMT2AMEN1L3MBTL1
SCHEMBL12834659 0.64 TDP1 (0.41) TDP1KMT2AMEN1CYP2D6SMN1; SMN2
SCHEMBL410306 0.63 TSHR (0.39) CYP2D6ALDH1A1CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140336208-A1 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2014-11-13 US disclosed
US-20120035195-A1 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS SIENA BIOTECH S.P.A., AN ITALIAN COMPANY (IT) 2012-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140336208-A1 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS BACE2, BACE1, PSEN2 TDP1 492/4885KMT2A 1384/4885MEN1 408/4885
US-20120035195-A1 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS BACE2, BACE1, PSEN2 TDP1 492/4885KMT2A 1384/4885MEN1 408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.